As PRMT1 is a major type I PRMT, it is not surprising that its enhanced expression is mirrored by increased ADMA content in systemic circulation in lung cancer patients as compared to nontumor control subjects [47]. This evidence concerns the gene PRMT1 and lung carcinoma.